Cell Biology Immune Response Treatment 
Drug Target Review
OCTOBER 16, 2023
As we explore translatability, technological advancements and the integration of artificial intelligence (AI), we envision the potential role of PDOs throughout the entire medicine creation pipeline, from target identification to personalised clinical treatments, ultimately reducing costs and improving patient outcomes.
Drug Discovery World
APRIL 14, 2023
He is being recognised for his fundamental discoveries dedicated to characterising the genetic drivers of human B-cell lymphomas and for uncovering new avenues for cancer prevention and therapy that have been routinely exploited clinically to diagnose and determine novel therapeutic strategies for B-cell lymphoma.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 3, 2021
I look forward to working with Scott and his team at NexImmune to help advance and expand the Company’s research and development pipeline with the ultimate goal of developing next-generation immunotherapies for patients suffering from immune-mediated conditions related to cancers and autoimmune/inflammatory diseases,” Dr. Zeldis commented. “It
Broad Institute
OCTOBER 11, 2023
By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cell biology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. When I began my PhD I completely switched my focus, and I haven’t looked back,” said Manguso.
Drug Target Review
NOVEMBER 17, 2023
NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).
Drug Discovery World
DECEMBER 15, 2022
As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Likewise, Lessard et al.
Drug Discovery World
NOVEMBER 8, 2023
Helmut Salih, MD, Professor for Translational Immunology, Medical Director, Clinical Collaboration Unit Translational Immunology, University Hospital Tuebingen and DKFZ Heidelberg, Germany; Co-Founder, TWYCE GmbH, on: ‘An optimised IgG-Based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers’.
Expert insights. Personalized for you.
122 
Let's personalize your content